ORIGINAL RESEARCH

MicroRNA-371–3 cluster as biomarkers for the diagnosis and prognosis of cancers

Bei Pan[1,*]
Bangshun He[1,*]
Xueni Xu[1,2]
Xiangxiang Liu[1]
Tao Xu[1]
Mu Xu[1]
Xiaoxiang Chen[1,2]
Kaixuan Zeng[1,2]
Kang Lin[3]
Xiuxiu Hu[1,2]
Li Sun[4]
Yuqin Pan[1]
Huiling Sun[1]
Shukui Wang[1,3,5]

[1]General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China; [2]School of Medicine, Southeast University, Nanjing 210009, People's Republic of China; [3]Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China; [4]Department of Laboratory Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, People's Republic of China; [5]Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China

*These authors contributed equally to this work

Correspondence: Shukui Wang
General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, No. 68, Changle Road, Nanjing 210006, People's Republic of China
Tel +86 255 227 1000
Fax +86 255 227 1000
Email sk_wang@njmu.edu.cn

Purpose: To date, increasing evidences have demonstrated that the aberrant expression of miR-371–3 cluster has been verified in various cancers and could be potentially used as a biomarker for tumor diagnosis and prognosis. To explore the role of miR-371–3 cluster in tumor diagnosis and prognosis, we conducted this study based on the published data.

Methods: We searched electronic databases (PubMed, EMBASE and Web of Science databases) (Jan 1, 2007 to Jun 1, 2018). The pooled sensitivity, specificity and area under the curve (AUC) of summary receiver operator characteristic (SROC) curve were used for diagnostic values, meanwhile the pooled hazard ration (HR) and 95% CI were used to explore the prognosis capacity of miR-372 and miR-373. In addition, the publication bias of the enrolled studies was tested and a sensitivity analysis of each study was performed to evaluate the stability of the pooled result.

Results: A total of eleven eligible studies containing six eligible studies containing 870 participants for diagnosis and 1218 cancer cases for prognosis were selected for this study. For diagnosis, the pooled results revealed that the miR-371 (sensitivity: 0.85, specificity: 0.92, AUC: 0.92) and miR-373 (sensitivity: 0.81, specificity: 0.93, AUC: 0.93) could be used as diagnostic biomarkers. For prognosis, we observed that elevated miR-372 indicated poor prognosis (HR=2.31, 95% CI: 1.04–5.14), especially in the cutoff value subgroup of median (HR=2.62, 95% CI: 1.54–4.46). In addition, pooled results showed that expression of miR-373 was not related to prognosis because of the significant heterogeneity, and the high miR-373 expression presented favorable prognosis in Asians (HR=0.34, 95% CI: 0.23–0.50) after omitting the study of heterogeneity origin.

Conclusion: The current studies demonstrated that miR-371 and miR-373 could be predictive tumor diagnostic biomarkers and the expression of miR-372 and miR-373 may indicate prognosis of cancer patients.

Keywords: cancer, miR-371, miR-372, miR-373, diagnosis, prognosis, biomarkers

Introduction

MicroRNAs (miRNAs), a primary class of endogenous, small, and noncoding RNA containing 18–24 nucleotides, have been found to have vital functions in post-transcriptional regulation of genes.[1] MiRNAs degrade transcription and repress translation via implicating in target messenger RNA (mRNA) to form RNA-induced silencing complexes (RISCs), and consequently lead to mRNA decapping and deadenylation.[2] There have been overwhelming evidence suggesting that miRNAs dysregulation in cancers could affect the biological behaviors of cells, such as abnormal proliferation, invasion, metastasis and epithelial-mesenchyme transition (EMT) of cancer cells, by influencing oncogenes and tumor-suppressor

genes.[3] Therefore, abnormal miRNAs expression could be potentially used as diagnosis and prognosis tumor biomarkers, and miRNAs also could be a treatment target.

MicroRNA-371–3 (miR-371–3) cluster locates on chromosome 19 and has three members, miR-371, MiR-372 and miR-373. MiR-371–3 cluster has been discussed to be involved in several diseases, such as canine visceral leishmaniasis,[4] stroke,[5] Kawasaki diseases,[6] colon cancer,[7] and moreover, it's role in the pathology of cancers is currently being focused on in several studies.[8–11] MiR-372 and miR-373 were reported to have the capacity to activate wild-type p53, counteract p53-mediated CDK inhibition and nourish oncogenic RAS to promote testicular germ cell cancerous process,[12] and up regulated miR-371–3p could reverse the acquired drug resistance and improve overall survival of cancer patients.[8] For miR-372, over-expression represses insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) to suppress cancer proliferation and metastasis.[13] For miR-373, it has been identified as being significantly elevated in lymph node-positive breast tumor samples, indicating that it plays a role in invasion and metastasis of tumors.[14] However, there are some reports holding different attitudes that down regulation of miR-373 in non-small-cell-lung-cancer (NSCLC) cells was observed to be associated with suppression of the cell EMT, proliferation, migration, and invasion.[15] Therefore, the role of miR-371–3 in development and progression of cancers remains obscure. In addition, the cluster was also reported as a diagnostic or prognostic biomarker, but the conclusions have remained elusive. MiR-371 and miR-372 in serum was reported to have a diagnostic value for germ cell tumors,[16] testicular germ cell cancer,[17] gastric cancer,[18] pancreatic cancer,[19] and breast cancer,[20,21] respectively. However, for miR-371, the sensitivity and specificity ranged from 75% to 98.60%, and 63.41% to 99.00% with AUC from 0.715 to 0.929, respectively and for miR-372, the sensitivity and specificity ranged from 68.00% to 96.80%, and 84.3% to 100% with AUC from 0.84 to 0.879, respectively. Such a varied result was arose from the different sample size, cut-off value, or cancer types. On the other hand, studies have evaluated the prognostic value of miR-372 and miR-373 for cancers, and reported they could serve as favorable survival indicators,[15,19,22–24] as well as adverse survival indicators.[25–30] Therefore, the diagnostic and prognostic values of miR-371–3 cluster are unclear currently. Hence, considering the disputable evaluation of the miR-371–3 cluster, this study were performed to integrate

related published studies to evaluate the potential role of these miRNAs as diagnostic and prognostic biomarkers in various cancers.

Materials and methods
Search strategy
To identify the related published articles, we searched three databases including PubMed, Web of Science, and Embase between Jan 1, 2007, and Jun 1, 2018, by the following keywords restricting, namely ('microRNA-371′ OR 'miR-371′ OR 'microRNA-372′ OR 'miR-372′ OR 'microRNA-373′ OR 'miR-373′ OR 'microRNA-371–3′ OR 'miR-371–3′) and ("carcinoma" OR "cancer" OR "neoplasm" OR "tumor"). To get additional articles, some potential related articles were included for full-text review based on the headline and abstract, and the references of full-text articles were also traced.

Inclusion and exclusion criteria
Inclusion criteria for articles identification were as following: 1) the patients reported were definitively diagnosed by the gold standard; 2) the expression of miR-371 or miR-372 or miR-373 were detected in body fluids, such as plasma, serum, tissue or sputum; 3) the diagnostic or prognostic value of one or more of the miR-371–3 cluster were connected; and 4) the sufficient data were provided to extract or calculate the diagnostic value for true positives (TP), false positives (FP), false negatives (FN), and true negatives (TN) and the prognostic value for overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), or disease-free survival (DFS).

We deemed the studies which had one of the following features as ineligible: 1) non-English publications; 2) lacking indispensable data for meta-analysis; and 3) containing duplicate data.

The NOS scale was applied to evaluate the quantity of articles before we excluded the inappropriate ones. We strictly followed the principles of the scale to award scores for each item and the articles scoring 6 or more were selected out of full marks of 9 points.

Data extraction and checking
Two authors reviewed and extracted information from the studies using a uniform criteria list independently. The extracted information below were concerned with outcome indicator: date of publication, type of microRNA, nationality of case, dominant ethnicity of case, mean or median

age of participants, kinds of malignant disease, source of data, size of research cohort, sampling method, detection method, follow-up time, HR and 95%CI, cut-off value, grade of cancer, and diagnostic power (including TP, FP, TN and FN).

Statistical analysis

To explore the performance of the cancer process and cancer outcomes impacted by dysfunction of miR-371–3, we pooled the HR of miR-372 and miR-373 expression for OS/RFS/PFS/DFS (high expression vs low expression). The data of two studies which didn't present directly were extracted from the Kaplan-Meier survival curves via the way Tierney reported.[31] In addition, Engauge Digitizer version 4.1 was used to recognize the graphical survival plots. The effects of heterogeneity were investigated by Chi-square test and I^2 statistic. If I^2 was >50% or $P<0.05$, a random-effects model was applied; or else a fixed-effects model was selected.[32] Sources of heterogeneity across contained articles were investigated with stratified analyses. We executed funnel plots, Begg's and Egger's tests to identify publication bias. With respect to diagnostic power, the bivariate regression model was used to combine sensitivity, specificity, positive likelihood ratios (PLRs), negative likelihood ratios (NLRs), and diagnostic odds ratio (DOR) with 95% CIs, based on the original statistics from the diagnostic four-fold table. We established summary receiver operator characteristic (SROC) curve and figured out the corresponding area under the SROC curve (AUC) based on the sensitivity and specificity of each study. Potential sources of heterogeneity were tested by the subgroup of participant characteristics and meta-regression. In addition, we adopted Deeks' funnel plot to describe the publication bias.

The data for prognosis was calculated by the STATA (11.0) software. We deemed it was not statistically significant if $P>0.05$, on the contrary, it would be elaborated.

Results

Eligible studies

We searched the three databases and 231 (PubMed, Web of science and Embase) articles matched the keywords. After screening headline, abstract, authors and their institutions, we identified that 18 studies were duplicates, and 185 articles were systematic reviews, letters, meta-analyses, or not related to the topic. And then, 28 eligible studies with available date were enrolled for the data extraction.

Due to lack of crucial statistic data, a total of 16 eligible studies were included finally, with a combination of eleven studies for prognostic and six studies for diagnostic meta-analysis (Figure 1).

The enrolled 16 studies recruited 1,318 participants totally. As for prognosis, five studies (n=538) were prospective studies of the impact of miR-373 on the survival rate of cancer patients.[15,19,23,24,30] The data related to miR-372 was extracted from five studies (n=580).[22,25,27–29] Moreover, one study (n=100) contained both miR-372 and miR-373 for prognostic value.[26] Regarding diagnosis, miR-371 was presented by three studies (n=497),[16–18] and three studies (n=373) were linked to miR-373.[19–21]

Diagnostic meta-analysis
Study characteristics

Six articles which discussed the role of miR-371 and miR-373 in diagnosis of cancers were selected and the details of participants are presented in Table 1. For miR-371, two studies explored germ cell tumors and the other one was concerned with gastric cancer; and for miR-373, one study was focused on pancreatic cancer and two studies were about breast cancer. In all enrolled studies, quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect expression of miRNAs and all the samples were collected from serum except one which was taken from plasma.

Expression of miR-371/3 and diagnosis

To discern whether the miR-371–3 level in serum of patients correlated with cancer development, we pooled the diagnostic parameters shown as forest plots. For miR-371, the pooled sensitivity, specificity and AUC of SROC were 0.85 (95% CI: 0.75–0.92, $P_{Heterogeneity}$=0.02, I^2=69.64), 0.92 (95% CI: 0.76–0.98, $P_{Heterogeneity}$<0.001, I^2=93.38) and 0.92 (Figure 2A, 2B). For miR-373, the pooled sensitivity, specificity and AUC of SROC were 0.81 (95% CI: 0.69–0.89, $P_{Heterogeneity}$=0.02, I^2=69.09), 0.93 (95% CI: 0.82–0.98, $P_{Heterogeneity}$=0.03, I^2=65.42) and 0.93 (Figure 3A, B).

Prognostic meta-analysis
Study characteristics and quality assessment

The dominant characteristics of the included eleven studies are summarized in Tables 2 and 3. For miR-372, the expression of miRNA was detected by qRT-PCR except one which was detected by in situ hybridization (ISH) and all six studies performed target miRNA expression

Figure 1 Flow diagram of the study selection process.

screening in tumor tissues and corresponding para-carcinoma tissues. There were two articles evaluating HR about hepatocellular carcinoma (HCC) and the other four studies were about urothelial carcinoma (UC), oral squamous cell carcinoma (OSCC), colorectal cancer (CRC), and gliomas, respectively. For miR-373, the included six studies detected miR-373 expression with qRT-PCR, two of the six presented prognostic value in the serum samples and four studies in tissue samples. Bladder cancer (BCa), pancreatic cancer, non-small cell lung cancer (NSCLC), gliomas, oral squamous cell carcinoma (OSCC) and epithelial ovarian cancer (EOC) were explored. To assess the quality of enrolled studies, we adopted the Newcastle-Ottawa Scale (NOS)[33] to score the studies based on nine criteria (Tables 2 and 3).

Expression of miR-372 and prognosis

The association of miR-372 cluster relative expression (low or high) to prognosis was evaluated by seven studies, and the critical value of miRNA cluster was defined separately by each author. Pooled results showed that elevated miR-372 was associated with poor prognosis (high

expression vs low expression: HR=2.31, 95% CI: 1.04–5.14, $P_{Heterogeneity}$<0.001, I^2=87.9%) (Figure 4).

To identify the origin of the heterogeneity among studies, we performed subgroup analyses for race, main assay method, and cutoff value. There were no associations between miR-372 and the race subgroup, but a significant connection of up-regulated miR-372 with poor prognosis was found in the median of the cutoff subgroup (HR=2.62, 95% CI: 1.54–4.46, $P_{Heterogeneity}$=0.139, I^2=45.3%). The pooled results of the subgroup with qRT-RCR method showed that high expression of miR-372 indicated poor prognosis exceptfor one study with ISH (HR=2.94, 95% CI: 1.82–4.74, $P_{Heterogeneity}$=0.101, I^2=48.4%) (Figure 5, Table 4).

Expression of miR-373 and prognosis

Six studies involving miR-373 were included in this study, and there was one study reporting on miR-372 and miR-373 simultaneously.[26] The pooled results showed that there was no significant association between expression of miR-373 and prognosis (HR=0.68, 95% CI: 0.27–1.69, $P_{Heterogeneity}$<0.001, I^2=90.4%) (Figure 4).

Table 1 Characteristics of the studies included for diagnosis in the meta-analysis

Author	Year	microRNA	Ethnicity	Cancer type	Cancer grade	Sample type	Mean/Median age (years)		Sample size		Diagnostic power				Sensitivity	Specificity	AUC	Cut-off value	Method
							Ca	Co	Ca	Co	TP	FP	TN	FN					
Dieckmann	2017	miR-371–3p	Caucasian	Germ cell tumours	CS1	Serum	38.5	38	107	106	87	8	98	20	81.40%	92.50%	/	Median	qRT-PCR
					CS2–CS3				43		42	8	98	1	98.60%	92.50%	/	/	
Syring	2014	miR-371–3p	Caucasian	Testicular germ cell cancer		Serum	NM	NM	59	101	50	1	100	9	84.70%	99.00%	0.929	0.004	qRT-PCR
Liu	2012	miR-371-5p	Asian	Gastric cancer	I–IV	Serum	56	58	40	41	30	15	26	10	75.00%	63.41%	0.715	6.66	qRT-PCR
Hua	2017	miR-373	Asian	Pancreatic cancer	I–IV	Serum	NM	NM	103	50	83	8	42	20	80.60%	84.30%	0.852	Median	qRT-PCR
Eichelser	2013	miR-373	Caucasian	Breast cancer	M0	Serum	65	65	120	40	92	0	40	28	76.60%	100.00%	0.879	/	qRT-PCR
					M1				32		31	2	38	1	96.80%	94.10%	/	/	
Chen	2013	miR-373	Caucasian	Breast ductal carcinoma	I–IV	Plasma	49	47	35	25	24	3	22	11	68.00%	89.00%	0.84	6.97	qRT-PCR

Notes: M0, patients with primary breast cancer after surgery and before chemotherapy; M1, patients with distant metastases at diagnosis (We roughly incorporated M0 into the early stage, and correspondingly incorporate M1 into the late stage.); qRT-PCR, quantitative real-time PCR.
**Abbreviations:** NM, not mentioned; CS, clinical stage.

Figure 2 Diagnostic value of miR-371. (**A**) Forest plots. (**B**) SROC curve.

Figure 3 Diagnostic value of miR-373. (**A**) Forest plots. (**B**) SROC curve.

Table 2 Characteristics of the studies included for miR-372 prognosis in tissue

| First author	Year	Ethnicity	Age(median/mean)	Malignant disease	Survival indicator	Follow up months	Method	Cut-off value	Case number		OS		RFS/PFS/DFS		NOS sore
									H	L	HR(95%CI) (U/M)	P-value	HR (95%CI) (U/M)	P-Value	
Bellmunt	2016	Caucasian	NM	UC	PFS	24	qRT-PCR	Median	40	40			1.73 (1.04, 2.89) U/ 1.70 (1.00, 2.89) M	0.05 U	5
Tu	2015	Asian	52.6	OSCC	DFS	160	qRT-PCR	Median	50	50			2.57 (1.20–5.48) U	0.002 U	6
Wu	2015	Asian	NM	HCC	OS	70	ISH	Mean	33	87	0.57 (0.38–0.85) U/ 0.53 (0.35–0.83) M	0.006 U/ 0.005 M			6
Li	2013	Asian	42	Gliomas	RR	148	qRT-PCR	Mean	78	50	4.37 (2.11–8.93) M	0.008 M			7
Yamashita	2012	Asian	66.8	CRC	OS	70	qRT-PCR	Median	72	72	2.03 (1.006–4.351) U/ 2.76 (1.322–6.110) M	0.048 U/ 0.006 M			6
Gu	2012	Asian	NM	HCC	OS/RFS	38	qRT-PCR	Median	65	43	20.36 (2.90–42.32) U/ 9.53 (1.74–28.67) M	0.001 U/ 0.008 M	12.73 (2.31–30.87) U/ 6.83 (1.51–19.05) M	0.0006 U/ 0.01 M	6

Note: qRT-PCR, quantitative real-time PCR; ISH, in situ hybridization; H, high expression; L, low expression; U, univariate analysis, M, multivariate analysis.
Abbreviations: NM, not mentioned; UC, urothelial carcinoma; OSCC, oral squamous cell carcinoma; HCC, hepatocellular carcinoma; CRC, colorectal cancer.

Table 3 Characteristics of the studies included for miR-373 prognosis in the meta-analysis

First author	Year	Dominant ethnicity	Age(median/mean)	Malignant disease	Detected sample	Survival analysis	Source of HR	Follow-up months	Male/Female	Cut-off value	Case number		OS		RFS/PFS/DFS		NOS score
											H	L	HR (95%CI) (U/M)	P-value	HR(95%CI) (U/M)	P-value	
Zhang	2017	Asian	NM	BCa	Tissues	OS	Reported	24	27/13	NM	40	40	0.441 (0.210–0.699)U	0.17 U			7
Hua	2017	Asian	NM	Pancreatic cancer	Serum	OS	Reported	70	62/41	Median	50	53	0.192 (0.119–0.472) M	0.014 M			5
Wang	2017	Asian	58.67	NSCLC	Tissues	OS	SC	70	56/36	Median	46	46	0.37 (0.15.0.92)	<0.001			6
Jing	2017	Asian	NM	Gliomas	Tissues	OS/RFS	SC	60	113/57	NM	83	87	0.40 (0.145–0.549) M	0.0007	0.3 (0.157,0.613) M	<0.001	7
Tu	2015	Asian	52.6	OSCC	Tissues	DFS	Reported	160	47/3	Median	50	50			2.62 (1.47–4.64) U	0.001 U	6
Meng	2015		60	EOC	Serum	OS/PFS	Reported	136	/	NM	47	46	2.1 (1.0–4.3) U/ 2.9 (1.3–6.8) M	0.033 U/ 0.012 M	1.6 (0.9–2.9) U	0.099 U	8

Abbreviations: NM, not mentioned; SC, survival curve; R, retrospective; qRT-PCR, quantitative real-time PCR; H, high expression; L, low expression; U, univariate analysis; M, multivariate analysis; BCa, bladder cancer; NSCLC, non-small cell lung cancer; OSCC, oral squamous cell carcinoma; EOC, epithelial ovarian cancer.

Study ID		HR (95% CI)	% Weight

miR-373
Zhang,2017 — 0.44 (0.21, 0.70) — 8.73
Hua,2017 — 0.19 (0.12, 0.47) — 8.51
Wang,2017 — 0.37 (0.15, 0.92) — 7.89
Jing,2017 — 0.40 (0.14, 0.55) — 8.57
Meng,2015 — 2.90 (0.30, 6.80) — 8.12
TU,2015 — 2.62 (1.47, 4.64) — 8.79
Subtotal (I-squared=90.4%, P=0.000) — 0.68 (0.27, 1.68) — 50.61

miR-372
Bellmunt,2016 — 1.70 (1.00, 2.89) — 8.89
TU,2015 — 2.57 (1.20, 5.48) — 8.32
Wu,2015 — 0.53 (0.34, 0.83) — 9.09
Li,2013 — 4.37 (2.11, 8.93) — 8.42
Yamashita,2012 — 2.78 (1.32, 6.11) — 8.30
Gu,2012 — 9.53 (1.74, 28.67) — 6.37
Subtotal (I-squared=87.9%, P=0.000) — 2.31 (1.04, 5.14) — 49.39

Overall (I-squared=89.9%, P=0.000) — 1.25 (0.68, 2.31) — 100.00

NOTE: Weights are from random effects analysis

.5   1   1.5

Figure 4 Forest plot of extracted HR for the association of miR-372 and miR-373 expression with OS/RFS/PFS/DFS.

Due to the significant heterogeneity among studies, subgroup analyses for race, cutoff value and sample source were conducted. In the results of the race subgroup, we found miR-373 was not associated with prognosis (HR=0.51, 95 CI%: 0.20–1.31, $P_{Heterogeneity}$<0.01, I^2=89.8%), but elevated miR-373 predicted favorable prognosis in the Asian population (HR=0.338, 95% CI: 0.23–0.50, $P_{Heterogeneity}$=0.305, I^2=17.2%) after omitting one study. We failed to find any significant association between miR-373 expression and prognosis by high expression compared with low expression in the subgroups of sample source and cutoff value (Figure 6, Table 4).

Publication bias and sensitivity analyses

To evaluate the stability of the results, we conducted sensitivity analyses to calculate the HR and 95% CI by omitted studies one by one. For miR-373, results of pooled HR was stable; however, for miR-372, the HR was changed from 2.31 (95% CI: 1.04–5.14) to 2.94 (95% CI: 1.82–4.74) when one of the studies was discarded[24] (Figure 7).

Egger's and Begg's tests were utilized to evaluate publication bias of studies. As the figure shows, the symmetric funnel plots indicated that there were no significant publication biases for the miR-373 (t=−0.28, P=0.792), but for miR-372, publication biases were existent (t=3.33, P=0.029) (Figure 8).

Discussion

This study included 16 studies devoted to exploring the diagnostic and prognostic value of miR-371–3 cluster for cancers, and the pooled result showed that the members of miR-371–3 cluster could serve as cancer diagnosis biomarkers and prognostic indicators.

We observed miR-371 and miR-373 have diagnostic value for cancer based on pooled results of seven studies. In fact, studies have verified that miR-371–3 cluster could be used as a biomarker for cancer screening when combined with other miRNAs.Razzak et al[34] and Kim et al[35] reported that a panel of three miRNAs (mir-21, mir-210, mir-372) have sensitivity and specificity of 67% and 90%, respectively; and that five miRNAs (miR-21, miR-143, miR-155, miR-210, and miR-372) yielded a diagnostic sensitivity of 85.7% and specificity of 100% for early NSCLC detecting.[34,35] Similarly, in breast cancer, it has been reported that, compared with miR-373, the

A

B

Figure 5 Forest plots of the miR-372 according to subgroup. (**A**) Cutoff value subgroup. (**B**) Detection method subgroup. (**C**) Race subgroup.

C

miR-372
Method subgroup

Figure 5 (Continued).

Table 4 The pooled associations between characteristic subgroups of miR-371—3 expression and prognosis of patients

microRNA	Subgroup	Number of studies	Number of cases (High/low)	HR (95% CI)	Heterogeneity (I^2)	P-values
miR-372	Total	6	338/342	2.31 (1.04,5.14)	87.9%	<0.001
	Race					
	Asian	5	298/302	2.55 (0.90,7.25)	90.2%	<0.001
	Caucasian	1	40/40	1.70 (1.00,2.89)	/	/
	Method					
	qRT-PCR	5	305/255	2.94 (1.82,4.74)	48.4%	0.101
	ISH	1	33/87	0.53 (0.35,0.83)	/	/
	Cutoff					
	Median	4	227/208	2.62 (1.54,4.46)	45.3%	0.139
	Mean	2	111/137	1.50 (0.19,11.74)	95.8%	<0.001
miR-373	Total	6	316/322	0.68 (0.27,1.68)	90.04%	<0.001
	Race					
	Asian	5	269/276	0.51 (0.20, 1.31)	89.8%	<0.001
	Caucasian	1	47/46	2.90 (1.27,6.63)	/	/
	Sample source					
	Tissue	4	172/177	0.66 (0.24,1.79)	88.9%	<0.001
	Serum	2	97/99	0.74 (0.05,10.57)	95.9%	<0.001
	Cutoff					
	NM	3	170/173	0.78 (0.25,2.42)	87.7%	<0.001
	Median	3	146/149	0.58 (0.27,1.69)	94.4%	<0.001

Abbreviations: NM, not mentioned; qRT-PCR, quantitative real-time PCR; ISH, in situ hybridization.

A

B

Figure 6 Forest plots of the miR-373 according to subgroup. (**A**) Cutoff value subgroup. (**B**) Race subgroup. (**C**) Sample source subgroup.

C

miR-373

Sample source subgroup

Study ID	HR (95% CI)	% Weight
Tissue		
Zhang,2017	0.44 (0.21, 0.70)	17.19
Wang,2017	0.37 (0.15, 0.92)	15.69
Jing,2017	0.40 (0.14, 0.55)	16.90
Tu,2015	2.62 (1.47, 4.64)	17.30
Subtotal (I-squared=88.9%, P=0.000)	0.66 (0.24, 1.79)	67.09
Serum		
Hua,2017	0.19 (0.12, 0.47)	16.80
Meng,2015	2.90 (1.30, 6.80)	16.11
Subtotal (I-squared=95.9%, P=0.000)	0.74 (0.05, 10.57)	32.91
Overall (I-squared=90.4%, P=0.000)	0.68 (0.27, 1.68)	100.00

NOTE: Weights are from random effects analysis

.5   1 1.5

Figure 6 (Continued).

combination of miR-373 and miR-10b could elevate the sensitivity and specificity from 68% and 89% to 72% and 94.3%,[21] and, in germ cell tumors detection, a panel of miR-372-3p, miR-373-3p and miR-367-3p can increase sensitivity of miR-371a-3p from 88.7% to 92%.[16] The result of these studies which are inconsistent with published data suggest that the combination of miR-371–3 cluster could be a favorable diagnostic biomarker for cancers. Recently, some reliable evidence has suggested that miR-371 and miR-373 could affect tumor initiation, cell proliferation and stemness of cancer cells via several complicated pathways. In metastasis-derived tumor initiated cells (TICs), TGFβ receptor 2 (TGFBR2), an identified target of miR-371–3, were repressed and the miR-371–3/TGFBR2/inhibitor of DNA binding 1 signaling pathway showed credible connection to self-renewal of TIC.[7] MiR-373 regulated tumor cell proliferation and growth by prohibiting or enhancing multiple target genes expression, including large tumor suppressor homolog 2 (LATS2),[12,36] CD44,[14] nuclear factor I/B (NFIB),[37] and estrogen receptor (ER).[38] Moreover, the stemness of CRC cells was enhanced by miR-372/373 via repressing differentiation-related pathways, such as NFκB, MAPK/Erk, and VDR.[39]

For the predictive value of miR-372 and miR-373, upregulated miR-372 was associated with poor prognosis and the results were more stable after omitting one study with ISH method. The pooled results indicated that there was no significant association between miR-373 and cancer patient survival (OS/RFS/PFS/DFS). However, increased miR-373 was associated with favorable OS based on the Asian population from four studies; the opposite results of the excepted study may be due to the unbalanced proportion of sex ratio (male/female: 47/3). We speculated that the prognostic trend about race may be due to the lack of studies reported in Caucasians, and still no study has verified the relationship between the role of miR-372 in cancer prognosis and race differences. MiR-371–3 cluster could influence cancer progress and recurrence rate mainly via the following three points. Firstly, lymph node metastasis is the most common result for tumor recurrence. In invasive cancer cells, overexpression of miR-373 induced by the zinc-dependent factor CREB could not only further down

Figure 7 Sensitivity analyses. (**A**) miR-372. (**B**) miR-373.

regulate TP53INP1 (nuclear protein), LATS2 or CD44 for breast and pancreatic cancer,[14,40] but suppress the large tumor suppressor homolog 2 (LATS2), leading to p53 pathway restrained in TGCTs.[41] Secondly, the emergence of drug resistance is a growing problem. Silenced miR-373 which induced by DNA methylation was reported to target RelA and PIK3CA mRNA, contributed to cisplatin sensitivity and tumor growth suppressed in lung cancer.[42] Lastly, the tumor microenvironment is an indispensable factor to affect tumor development. Under hypoxia, the expression of miR-373 was increased in breast cancer cell line (MCF-7) and cervical

cancer cell line (HeLa), which could lead to disordering of glucose metabolism and apoptotic pathway.[43]

There was obvious heterogeneity among the published data we included. These opposite results may be due to the difference of detection methods and cutoff value. For example, decreased miR-372 in HCC tissues reported by Wu et al[22] was detected by in situ hybridization, while Gu et al[29] showed the opposite outcomes by qRT-PCR; meanwhile, miR-372 was down regulated in HepG2 and SMMC7721 cell lines by Wu et al but up-regulated in the same HCC cell lines by Gu et al,

Figure 8 Publication bias analysis. (**A**) miR-372. (**B**) miR-373.

who compared with different normal human hepatocyte. The different reference object and study method could result in the different experimental results. As for cutoff value, four of six studies for miR-372 divided the patients into high and low expression group by the median expression of target miRNA and the other two studies selected mean expression of miR-372. For miR-373, half of the six studies chose median expression and the others didn't mention it. This subjective method of group division may also be one of the reasons for the heterogeneity.

There are several limitations in this article we must to point out. Firstly, the HR and corresponding 95% CIs of two articles for OS which were extracted from survival curves may be inaccurate and have a certain impact on the final results. Secondly, the documents we screened are all in English, and deviations could be caused by the language restrictions. Thirdly, the number of articles included may be too small to summarize the diagnostic and prognostic value of miR-371-3 cluster. Lastly, although human miR-371, miR-372 and miR-373 are clustered within 1.1kb on chromosome 19, several types of microRNA are derived from this cluster, such as miR-

371a-3p (previous ID: miR-371-3p), miR-371a-5p (previous ID: miR-371-5p), miR-371b-3p and miR-371b-5p (Figure S1). We combined the results and ignored the differences between miR-371-3p or miR-371-5p because up to date, there have been no studies concerned with the difference of miR-371-3p and miR-371-5p for the diagnostic or prognostic value. But it should be noted whether there are differences between mature miRNA of miR-371–3 cluster members when used as biomarkers, which should be considered by further studies.

In short, this study based on the published data suggested that the miR-3713 cluster member (miR-371/miR-373) in serum could be used as diagnostic biomarkers and that miR-372/miR-373 has a potential prognostic value for cancer survival.

Acknowledgments

Author contributions

All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small rnas with antisense complementarity to lin-14. *Cell*. 1993;75:843–854.
2. Carthew RW, Sontheimer EJ. Origins and mechanisms of mirnas and sirnas. *Cell*. 2009;136:642–655. doi:10.1016/j.cell.2009.01.035
3. Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microrna function and dysfunction in cancer. *Nat Rev Genet*. 2016;17:719–732. doi:10.1038/nrg.2016.134
4. Bragato JP, Melo LM, Venturin GL, Rebech GT, Garcia LE, Lopes FL. Relationship of peripheral blood mononuclear cells mirna expression and parasitic load in canine visceral leishmaniasis. *PloS One* 2018;13: e0206876.
5. Edwardson MA. Plasma microrna markers of upper limb recovery following human stroke. *PLoS One*. 2018;8:12558.
6. Zhang W, Wang Y. Serum mir-200c and mir-371-5p as the useful diagnostic biomarkers and therapeutic targets in Kawasaki disease. *BioMed Res Int*. 2017;2017:8257862.
7. Ullmann P, Rodriguez F, Schmitz M, et al. The mir-371 approximately 373 cluster represses colon cancer initiation and metastatic colonization by inhibiting the tgfbr2/id1 signaling axis. *Cancer Res* 2018;78:3793–3808. doi:10.1158/0008-5472.CAN-17-3003
8. Sahu N, Stephan JP, Cruz DD, et al. Functional screening implicates mir-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs. *Nat Commun*. 2016;7:12351. doi:10.1038/ncomms12351
9. Haan S, Letellier E, Guo H, et al. Microrna-371a-3p promotes progression of gastric cancer by targeting tob1. *Cancer Res*. 2019;443:179–188.
10. Classon M, Settleman J, Ullmann P, et al. The mir-371 approximately 373 cluster represses colon cancer initiation and metastatic colonization by inhibiting the tgfbr2/id1 signaling axis. *Nat Commun*. 2018;78:3793–3808.
11. Murray MJ, Huddart RA, Coleman N. The present and future of serum diagnostic tests for testicular germ cell tumours. *Nat Rev Urol*. 2016;13:715–725. doi:10.1038/nrurol.2016.170
12. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates mirna-372 and mirna-373 as oncogenes in testicular germ cell tumors. *Cell*. 2006;124:1169–1181. doi:10.1016/j.cell.2006.02.037
13. Huang X, Huang M, Kong L, Li Y. Mir-372 suppresses tumour proliferation and invasion by targeting igf2bp1 in renal cell carcinoma. *Cell Prolif*. 2015;48:593–599. doi:10.1111/cpr.12207
14. Huang Q, Gumireddy K, Schrier M, et al. The micrornas mir-373 and mir-520c promote tumour invasion and metastasis. *Nat Cell Biol*. 2008;10:202–210. doi:10.1038/ncb1681
15. Wang L, Qu J, Zhou L, Liao F, Wang J. Microrna-373 inhibits cell proliferation and invasion via targeting brf2 in human non-small cell lung cancer a549 cell line. *Cancer Res Treat*. 2018;50(3):936–949.
16. Dieckmann KP, Radtke A, Spiekermann M, et al. Serum levels of microrna mir-371a-3p: A sensitive and specific new biomarker for germ cell tumours. *Eur Urol*. 2017;71:213–220. doi:10.1016/j.eururo.2016.07.029
17. Syring I, Bartels J, Holdenrieder S, Kristiansen G, Muller SC, Ellinger J. Circulating serum mirna (mir-367-3p, mir-371a-3p, mir-372-3p and mir-373-3p) as biomarkers in patients with testicular germ cell cancer. *J Urol*. 2015;193:331–337. doi:10.1016/j.juro.2014.07.010
18. Liu H, Zhu L, Liu B, et al. Genome-wide microrna profiles identify mir-378 as a serum biomarker for early detection of gastric cancer. *Cancer Lett*. 2012;316:196–203. doi:10.1016/j.canlet.2011.10.034
19. Hua Y, Chen H, Wang L, et al. Low serum mir-373 predicts poor prognosis in patients with pancreatic cancer. *Cancer Biomarkers*. 2017;20:95–100. doi:10.3233/CBM-170231
20. Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. Deregulated serum concentrations of circulating cell-free micrornas mir-17, mir-34a, mir-155, and mir-373 in human breast cancer development and progression. *Clin Chem*. 2013;59:1489–1496. doi:10.1373/clinchem.2013.205161
21. Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of circulating mirna-10b and mirna-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. *Tumour Biol*. 2013;34:455–462. doi:10.1007/s13277-012-0570-5
22. Wu G, Wang Y, Lu X, et al. Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma. *BMC Cancer*. 2015;15:182. doi:10.1186/s12885-015-1584-3
23. Zhang Q, Wang C, Miao S, Li C, Chen Z, Li F. Enhancing e-cadherin expression via promoter-targeted mir-373 suppresses bladder cancer cells growth and metastasis. *Oncotarget*. 2017;8:93969–93983. doi:10.18632/oncotarget.21400
24. Jing SY, Jing SQ, Liu LL, Xu LF, Zhang F, Gao JL. Down-expression of mir-373 predicts poor prognosis of glioma and could be a potential therapeutic target. *Eur Rev Med Pharmacol Sci*. 2017;21:2421–2425.

25. Bellmunt J, Zhou CW, Mullane SA, et al. Association of tumour microrna profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. *Br J Cancer*. 2016;115:12–19. doi:10.1038/bjc.2016.146

26. Tu HF, Chang KW, Cheng HW, Liu CJ. Upregulation of mir-372 and −373 associates with lymph node metastasis and poor prognosis of oral carcinomas. *Laryngoscope*. 2015;125:E365–370. doi:10.1002/lary.25464

27. Li G, Zhang Z, Tu Y, et al. Correlation of microrna-372 upregulation with poor prognosis in human glioma. *Diagn Pathol*. 2013;8:1. doi:10.1186/1746-1596-8-1

28. Yamashita S, Yamamoto H, Mimori K, et al. Microrna-372 is associated with poor prognosis in colorectal cancer. *Oncology*. 2012;82:205–212. doi:10.1159/000336809

29. Gu H, Guo X, Zou L, Zhu H, Zhang J. Upregulation of microrna-372 associates with tumor progression and prognosis in hepatocellular carcinoma. *Mol Cell Biochem*. 2013;375:23–30. doi:10.1007/s11010-012-1521-6

30. Meng X, Pantel MV, Schwarzenbach H. Diagnostic and prognostic relevance of circulating exosomal mir-373, mir-200a, mir-200b and mir-200c in patients with epithelial ovarian cancer. *Oncotarget*. 2016. doi:10.18632/oncotarget.7850

31. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials*. 2007;8:16. doi:10.1186/1745-6215-8-16

32. Mahid SS, Hornung CA, Minor KS, Turina M, Galandiuk S. Systematic reviews and meta-analysis for the surgeon scientist. *Br J Surg*. 2006;93:1315–1324. doi:10.1002/bjs.5596

33. Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25:603–605. doi:10.1007/s10654-010-9491-z

34. Razzak R, Bedard EL, Kim JO, et al. Microrna expression profiling of sputum for the detection of early and locally advanced non-small-cell lung cancer: A prospective case-control study. *Current Oncol*. 2016;23:e86–94. doi:10.3747/co.23.2830

35. Kim JO, Gazala S, Razzak R, et al. Non-small cell lung cancer detection using microrna expression profiling of bronchoalveolar lavage fluid and sputum. *Anticancer Res*. 2015;35:1873–1880.

36. Lee KH, Goan YG, Hsiao M, et al. Microrna-373 (mir-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (lats2) and stimulates proliferation in human esophageal cancer. *Exp Cell Res*. 2009;315:2529–2538. doi:10.1016/j.yexcr.2009.06.001

37. Guo H, Liu H, Mitchelson K, et al. Micrornas-372/373 promote the expression of hepatitis b virus through the targeting of nuclear factor i/b. *Hepatology*. 2011;54:808–819. doi:10.1002/hep.24441

38. Eichelser C, Stuckrath I, Muller V, et al. Increased serum levels of circulating exosomal microrna-373 in receptor-negative breast cancer patients. *Oncotarget*. 2014;5:9650–9663. doi:10.18632/oncotarget.2520

39. Wang LQ, Yu P, Li B, et al. Mir-372 and mir-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways. *Mol Oncol*. 2018;12:1949–1964. doi:10.1002/1878-0261.12376

40. Zhang Y, Yang J, Cui X, et al. A novel epigenetic creb-mir-373 axis mediates zip4-induced pancreatic cancer growth. *EMBO Mol Med*. 2013;5:1322–1334. doi:10.1002/emmm.201302507

41. Wei F, Cao C, Xu X, Wang J. Diverse functions of mir-373 in cancer. *J Transl Med*. 2015;13:162. doi:10.1186/s12967-015-0541-x

42. Adi Harel S, Bossel Ben-Moshe N, Aylon Y, et al. Reactivation of epigenetically silenced mir-512 and mir-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth. *Cell Death Differ*. 2015;22:1328–1340. doi:10.1038/cdd.2014.221

43. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. Microrna regulation of DNA repair gene expression in hypoxic stress. *Cancer Res*. 2009;69:1221–1229. doi:10.1158/0008-5472.CAN-08-2516

Supplementary materials

Figure S1 The genomic localization chart and sequences of miR-371-3 cluster.

Table S1 Characteristics of studies included in the meta-analysis

First author	Year	miRNA	Ethnicity	Cancer type	Sample type	Method	Cancer grade	Case (H)	Control (L)
Liu	2012	miR-371-5p	Asian	Gastric cancer	Serum	qRT-PCR	I–IV	40	41
Yamashita	2012	miR-372	Asian	CRC	Tissue	qRT-PCR	\	72	72
Gu	2012	miR-372	Asian	HCC	Tissue	qRT-PCR	\	65	43
Li	2013	miR-372	Asian	Gliomas	Tissue	qRT-PCR	\	78	50
Eichelser	2013	miR-373	Caucasian	Breast cancer	Serum	qRT-PCR	M0	120	40
							M1	32	
Chen	2013	miR-373	Caucasian	Breast ductal carcinoma	Plasma	qRT-PCR	I–IV	35	25
Syring	2014	miR-371-3p	Caucasian	Testicular germ cell cancer	Serum	qRT-PCR	\	59	101
Tu	2015	miR-372	Asian	OSCC	Tissue	qRT-PCR	\	50	50
Tu	2015	miR-373	Asian	OSCC	Tissues	qRT-PCR	\	50	50
Meng	2015	miR-373	Caucasian	EOC	Serum	qRT-PCR	\	47	46
Wu	2015	miR-372	Asian	HCC	Tissue	ISH	\	33	87
Bellmunt	2016	miR-372	Caucasian	UC	Tissue	qRT-PCR	\	40	40
Dieckmann	2017	miR-371-3p	Caucasian	Germ cell tumours	Serum	qRT-PCR	CS1	107	106
							CS2–CS3	43	
Hua	2017	miR-373	Asian	Pancreatic cancer	Serum	qRT-PCR	I–IV	103	50
Zhang	2017	miR-373	Asian	BCa	Tissues	qRT-PCR	\	40	40
Hua	2017	miR-373	Asian	Pancreatic cancer	Serum	qRT-PCR	\	50	53
Jing	2017	miR-373	Asian	Gliomas	Tissues	qRT-PCR	\	83	87
Wang	2017	miR-373	Asian	NSCLC	Tissues	qRT-PCR	\	46	46

Note: M0, patients with primary breast cancer after surgery and before chemotherapy; M1, patients with distant metastases at diagnosis (We roughly incorporated M0 into the early stage, and correspondingly incorporate M1 into the late stage).
Abbreviations: qRT-PCR, quantitative real-time PCR; H, high expression; L, low expression; CS, clinical stage; UC, urothelial carcinoma; OSCC, oral squamous cell carcinoma; HCC, hepatocellular carcinoma; CRC, colorectal cancer; BCa, bladder cancer; NSCLC, non-small cell lung cancer; EOC, epithelial ovarian cancer.